Clinical trials: Dura Mater Nick Cut or Tear
Dura Mater Nick Cut or Tear, Hemostatis
Hemopatch Performance Evaluation: A Prospective Observational Registry
To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.
- Conditions
- Dura Mater Nick Cut or Tear, Hemostatis, Air Leakage, Body Fluid Leakage
- Trial name
- NCT03392662
- Testing
- Hemopatch
- Where
- 15 sites in Austria, Czechia and 3 more
- Volunteers
- 621 people
- Sponsor
- Baxter Healthcare Corporation
Dura Mater Nick Cut or Tear, Surgery
Duragen® Secure Post Marketing Clinical Follow-up (PMCF)
The purpose of this study is to gather information about post-market performance of DuraGen Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market clinical data to evaluate the presence of…
- Trial name
- NCT02225080
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Integra LifeSciences Corporation